EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force - PubMed (original) (raw)
Practice Guideline
EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force
S Evers et al. Eur J Neurol. 2009 Sep.
Abstract
Background: Migraine is one of the most frequent disabling neurological conditions with a major impact on the patients' quality of life.
Objectives: To give evidence-based or expert recommendations for the different drug treatment procedures in the particular migraine syndromes based on a literature search and the consensus of an expert panel.
Methods: All available medical reference systems were screened for the range of clinical studies on migraine with and without aura and on migraine-like syndromes. The findings in these studies were evaluated according to the recommendations of the European Federation of Neurological Societies (EFNS) resulting in level A, B, or C recommendations and good practice points.
Recommendations: For the acute treatment of migraine attacks, oral non-steroidal antiinflammatory drug (NSAID) and triptans are recommended. The administration should follow the concept of stratified treatment. Before intake of NSAID and triptans, oral metoclopramide or domperidone is recommended. In very severe attacks, intravenous acetylsalicylic acid or subcutaneous sumatriptan are drugs of first choice. Status migrainosus can be treated by cortoicosteroids, although this is not universally held to be helpful, or dihydroergotamine. For the prophylaxis of migraine, betablockers (propranolol and metoprolol) flunarizine, valproic acid, and topiramate are drugs of first choice. Drugs of second choice for migraine prophylaxis include amitriptyline, naproxen, petasites, and bisoprolol.
Similar articles
- EFNS guideline on the drug treatment of migraine - report of an EFNS task force.
Members of the task force:; Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sándor PS. Members of the task force:, et al. Eur J Neurol. 2006 Jun;13(6):560-72. doi: 10.1111/j.1468-1331.2006.01411.x. Eur J Neurol. 2006. PMID: 16796580 - Pharmacological approaches to migraine.
Diener HCh. Diener HCh. J Neural Transm Suppl. 2003;(64):35-63. doi: 10.1007/978-3-7091-6020-6_3. J Neural Transm Suppl. 2003. PMID: 12830928 Review. - Advances in pharmacological treatment of migraine.
Diener HC, Limmroth V. Diener HC, et al. Expert Opin Investig Drugs. 2001 Oct;10(10):1831-45. doi: 10.1517/13543784.10.10.1831. Expert Opin Investig Drugs. 2001. PMID: 11772289 Review. - [Alternatives to beta blockers in preventive migraine treatment].
Evers S. Evers S. Nervenarzt. 2008 Oct;79(10):1135-6, 1138-40, 1142-3. doi: 10.1007/s00115-008-2522-2. Nervenarzt. 2008. PMID: 18806984 Review. German. - New "triptans" and other drugs for migraine.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 1998 Oct 9;40(1037):97-100. Med Lett Drugs Ther. 1998. PMID: 9793036 No abstract available.
Cited by
- Atogepant for migraine prevention: a meta-analysis of safety and efficacy in adults.
Raja A, Asim R, Shuja MH, Raja S, Muhammad TS, Bajaj S, Ansari AH, Ali H, Magsi IA, Faridi MH, Sheikh HAH, Imran MJ, Ahmed M, Asghar MS. Raja A, et al. Front Neurol. 2024 Sep 27;15:1468961. doi: 10.3389/fneur.2024.1468961. eCollection 2024. Front Neurol. 2024. PMID: 39399876 Free PMC article. - European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention - part 4: propranolol.
Versijpt J, Deligianni C, Hussain M, Amin F, Reuter U, Sanchez-Del-Rio M, Uluduz D, Boucherie D, Zeraatkar D, MaassenVanDenBrink A, Sacco S, Lampl C, Gil-Gouveia R. Versijpt J, et al. J Headache Pain. 2024 Jul 24;25(1):119. doi: 10.1186/s10194-024-01826-y. J Headache Pain. 2024. PMID: 39044170 Free PMC article. - Intervening in the Premonitory Phase to Prevent Migraine: Prospects for Pharmacotherapy.
Karsan N, Goadsby PJ. Karsan N, et al. CNS Drugs. 2024 Jul;38(7):533-546. doi: 10.1007/s40263-024-01091-2. Epub 2024 May 31. CNS Drugs. 2024. PMID: 38822165 Review. - Presynaptic antiseizure medications - basic mechanisms and clues for their rational combinations.
Czapińska-Ciepiela EK, Łuszczki J, Czapiński P, Czuczwar SJ, Lasoń W. Czapińska-Ciepiela EK, et al. Pharmacol Rep. 2024 Aug;76(4):623-643. doi: 10.1007/s43440-024-00603-7. Epub 2024 May 22. Pharmacol Rep. 2024. PMID: 38776036 Free PMC article. Review. - Healthcare utilisation and economic burden of migraines among bank employees in China: a probabilistic modelling study.
Wei D, Wong LP, He X, Loganathan T. Wei D, et al. J Headache Pain. 2024 Apr 19;25(1):60. doi: 10.1186/s10194-024-01763-w. J Headache Pain. 2024. PMID: 38641794 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous